These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17313204)

  • 21. Bicalutamide: in early-stage prostate cancer.
    Carswell CI; Figgitt DP
    Drugs; 2002; 62(17):2471-79; discussion 2480-1. PubMed ID: 12421104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bicalutamide dosages used in the treatment of prostate cancer.
    Kolvenbag GJ; Nash A
    Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bicalutamide monotherapy for early stage prostate cancer: an update.
    Iversen P
    J Urol; 2003 Dec; 170(6 Pt 2):S48-52; discussion S52-4. PubMed ID: 14610410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
    Kolvenbag GJ; Iversen P; Newling DW
    Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Baert L; Tammela T; Chamberlain M; Carroll K; Gotting-Smith K; Blackledge GR
    Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bicalutamide treatment for locally advanced prostate cancer.
    Anderson J
    Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
    Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
    Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
    Tyrrell CJ; Kaisary AV; Iversen P; Anderson JB; Baert L; Tammela T; Chamberlain M; Webster A; Blackledge G
    Eur Urol; 1998; 33(5):447-56. PubMed ID: 9643663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Boccardo F; Rubagotti A; Barichello M; Battaglia M; Carmignani G; Comeri G; Conti G; Cruciani G; Dammino S; Delliponti U; Ditonno P; Ferraris V; Lilliu S; Montefiore F; Portoghese F; Spano G
    J Clin Oncol; 1999 Jul; 17(7):2027-38. PubMed ID: 10561254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bicalutamide in advanced prostate cancer. A review.
    Goa KL; Spencer CM
    Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
    Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns C; Borchers T; Morris T; Armstrong J;
    Prostate Cancer Prostatic Dis; 2005; 8(2):194-200. PubMed ID: 15931272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    McPartlin AJ; Glicksman R; Pintilie M; Tsuji D; Mok G; Bayley A; Chung P; Bristow RG; Gospodarowicz MK; Catton CN; Milosevic M; Warde PR
    Cancer; 2016 Aug; 122(16):2595-603. PubMed ID: 27219522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of bicalutamide-induced breast events.
    Sieber PR
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY; Segal G
    Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
    Serretta V; Altieri V; Morgia G; Nicolosi F; De Grande G; Mazza R; Melloni D; Allegro R; Ferraù F; Gebbia V
    Clin Genitourin Cancer; 2012 Sep; 10(3):174-9. PubMed ID: 22502790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.
    Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns CF; Navani S; Armstrong J
    Prostate Cancer Prostatic Dis; 2007; 10(1):87-93. PubMed ID: 17102802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
    Iversen P; Johansson JE; Lodding P; Lukkarinen O; Lundmo P; Klarskov P; Tammela TL; Tasdemir I; Morris T; Carroll K;
    J Urol; 2004 Nov; 172(5 Pt 1):1871-6. PubMed ID: 15540741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.